Two lenders win big in $74bn BMS Celgene merger

By Mike Turner
03 Jan 2019

The US’s Bristol-Myers Squibb (BMS) has picked two banks to provide the debt portion of its $74bn acquisition of biotech firm Celgene, in one of the biggest pharmaceuticals mergers in recent years.

Morgan Stanley and MUFG have provided fully committed debt financing for the acquisition, announced on Thursday. 

The US bank is also lead financial adviser to BMS on the deal, with Evercore and Dyal Co also advisers. JP Morgan and Citigroup are advising Celgene.

The deal values Celgene at $102.43 a ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.